Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Short-Course Levofloxacin for Acute Bacterial Exacerbation of Chronic Bronchitis
NCT00042718Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of levofloxacin in chronic bronchitis (CB) (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Clinical response rates based on signs and symptoms at posttherapy visit. Started Nov 2001; status: completed.
02
Drugs
levofloxacin
03
Conditions
chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT00042718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042718.